SEARCH

SEARCH BY CITATION

References

  • 1
    American Heart Association. Heart Disease and Stroke Statistics: 2004 Update. Available at: http:www.americanheart. org.Accessed January 23, 2004.
  • 2
    The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997; 157: 24132446.
  • 3
    Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):15571562.
  • 4
    Lerner DJ, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J. 1986;111(2):383390.
  • 5
    LaRosa JC. Understanding risk in hypercholesterolemia. Clin Cardiol. 2003;26(1 suppl 1):I3I6.
  • 6
    Thomas F, Bean K, Guize L, et al. Combined effects of systolic blood pressure and serum cholesterol on cardiovascular mortality in young (<55) men and women. Eur Heart J. 2002; 23: 528535.
  • 7
    Epstein F, Ostrander L, Johnson B, et al. Epidemiological studies of cardiovascular disease in a total community: Tecumseh, Michigan. Ann Intern Med. 1965; 62: 11701187.
  • 8
    Drawber T, Kannel W. An epidemiologic study of heart disease: the Framingham study. Nutr Rev. 1958; 16: 14.
  • 9
    National Heart, Lung, and Blood Institute. High blood cholesterol. Nutr Clin Care. 2003;6(3):108114.
  • 10
    de Bono D. Investigation and management of stable angina: revised guidelines. Heart. 1999;81(5):546555.
  • 11
    Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemic Pilot (ACIP) study two-year followup: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation. 1997; 95: 20372043.
  • 12
    Pepine CJ. Angina pectoris in a contemporary population: characteristics and therapeutic implications. Tides Investigators. Cardiovasc Drugs Ther. 1998;12(suppl 3):211216.
  • 13
    Staniforth AD. Contemporary management of chronic stable angina. Drugs Aging. 2001;18(2):109121.
  • 14
    Gill D, Mayou R, Dawes M, et al. Presentation, management and course of angina and suspected angina in primary care. J Psychosom Res. 1999;46(4):349358.
  • 15
    Lowe L, Greenland P, Ruth K, et al. Impact of cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med. 1998;158(18):20072014.
  • 16
    Hendrix KH, Riehle JE, Egan BM. Ethnic, gender, and agerelated differences in treatment and control of dyslipidemia in hypertensive patients. Ethn Dis. 2005; 15: 1116.
  • 17
    Penque S, Halm M, Smith M, et al. Women and coronary disease: relationship between descriptors of signs and symptoms and diagnostic and treatment course. Am J Crit Care. 1998;7(3):175182.
  • 18
    Steingart RM, Packer M, Hamm P, et al. Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med. 1991;325(4):226230.
  • 19
    Kuster GM, Buser P, Osswald S, et al. Comparison of presentation, perception, and six-month outcome between women and men >or = 75 years of age with angina pectoris. Am J Cardiol. 2003;91(4):436439.
  • 20
    Stewart A, Rao J, Osho-Williams G, et al. Audit of primary care angina management in Sandwell, England. J R Soc Health. 2002;122(2):112117.
  • 21
    Schulman KA, Berlin JA, Harless W, et al. The effect of race and sex on physicians' recommendations for cardiac catheterization. N Engl J Med. 1999;340(8):618626.
  • 22
    Chandra A, Compton S, Sochor M, et al. Untreated hypercholesterolemia in an emergency department chest pain observation unit population. Acad Emerg Med. 2002;9(7):699702.
  • 23
    Borghi C. Interactions between hypercholesterolemia and hypertension: implications for therapy. Curr Opin Nephrol Hypertens. 2002;11(5):489496.
  • 24
    Rader DJ. Therapy to reduce risk of coronary heart disease. Clin Cardiol. 2003;26(1):28.
  • 25
    Barter P. Treatment of dyslipidemia in high-risk patients: too little, too late. Int J Clin Pract Suppl. 2002; 130: 1519.
  • 26
    Egan BM, Lackland DT, Basile JN. American Society of Hypertension regional chapters: leveraging the impact of the clinical hypertension specialist in the local community. Am J Hypertens. 2002; 15: 372379.
  • 27
    Egan BM, Lackland DT. Strategies for cardiovascular disease prevention: importance of public and community health programs. Ethn Dis. 1998; 8: 228239.
  • 28
    Zanchetti A. Hyperlipidemia in the hypertensive patient. Am J Med. 1994;96(6A):3S8S.
  • 29
    Hendrix KH, Mayhan S, Lackland DT, et al. Prevalence, treatment, and control of chest pain syndromes and associated risk factors in hypertensive patients. Am J Hypertens. In press.
  • 30
    Jones PH. Low-density lipoprotein cholesterol reduction and cardiovascular disease prevention: the search for superior treatment. Am J Med. 2004;116(suppl 6A):17S25S.
  • 31
    Saini H, Arneja A, Dhalla N. Role of cholesterol in cardiovascular dysfunction. Can J Cardiol. 2004;20(3):333346.